These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24494779)

  • 1. Long-term use of protease inhibitors is associated with bone mineral density loss.
    Kinai E; Nishijima T; Mizushima D; Watanabe K; Aoki T; Honda H; Yazaki H; Genka I; Tanuma J; Teruya K; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):553-9. PubMed ID: 24494779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
    HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
    Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
    AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of bone mineral density in stable kidney transplant recipients.
    Gupta AK; Huang M; Prasad GV
    J Nephrol; 2012; 25(3):373-83. PubMed ID: 21928224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal study on physical fitness parameters influencing bone mineral density reduction in middle-aged and elderly women: bone mineral density in the lumbar spine, femoral neck, and femur.
    Iida T; Ikeda H; Shiokawa M; Aoi S; Ishizaki F; Harada T; Ono Y
    Hiroshima J Med Sci; 2012 Jun; 61(2):23-8. PubMed ID: 22916509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.
    Negredo E; Bonjoch A; Puig J; Echeverría P; Estany C; Santos JR; Moltó J; Pérez-Álvarez N; Ornelas A; Clotet B
    New Microbiol; 2015 Apr; 38(2):193-9. PubMed ID: 25938744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors.
    Tsai MS; Hung CC; Liu WC; Chen KL; Chen MY; Hsieh SM; Sheng WH; Sun HY; Shih TT
    J Microbiol Immunol Infect; 2014 Apr; 47(2):109-15. PubMed ID: 23073318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
    AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative contribution of HIV infection, demographics and body mass index to bone mineral density.
    Cotter AG; Sabin CA; Simelane S; Macken A; Kavanagh E; Brady JJ; McCarthy G; Compston J; Mallon PW;
    AIDS; 2014 Sep; 28(14):2051-60. PubMed ID: 25265073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
    Martin A; Moore C; Mallon PW; Hoy J; Emery S; Belloso W; Phanuphak P; Ferret S; Cooper DA; Boyd MA;
    AIDS; 2013 Sep; 27(15):2403-11. PubMed ID: 23921615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
    Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
    Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss.
    Nguyen TV; Sambrook PN; Eisman JA
    J Bone Miner Res; 1997 Jan; 12(1):124-35. PubMed ID: 9240735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation.
    Alcalde Vargas A; Pascasio Acevedo JM; Gutiérrez Domingo I; García Jiménez R; Sousa Martín JM; Ferrer Ríos MT; Sayago Mota M; Giráldez Gallego A; Gómez Bravo MA
    Transplant Proc; 2012; 44(6):1496-8. PubMed ID: 22841194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management.
    Mazzotta E; Ursini T; Agostinone A; Di Nicola AD; Polilli E; Sozio F; Vadini F; Pieri A; Trave F; De Francesco V; Capasso L; Borderi M; Manzoli L; Viale P; Parruti G
    AIDS Patient Care STDS; 2015 Apr; 29(4):169-80. PubMed ID: 25692868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of bone density in human immunodeficiency virus-infected women.
    Dolan SE; Kanter JR; Grinspoon S
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2938-45. PubMed ID: 16735489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMD is reduced in HIV-infected men irrespective of treatment.
    Amiel C; Ostertag A; Slama L; Baudoin C; N'Guyen T; Lajeunie E; Neit-Ngeilh L; Rozenbaum W; De Vernejoul MC
    J Bone Miner Res; 2004 Mar; 19(3):402-9. PubMed ID: 15040828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
    Rivas P; Górgolas M; García-Delgado R; Díaz-Curiel M; Goyenechea A; Fernández-Guerrero ML
    HIV Med; 2008 Feb; 9(2):89-95. PubMed ID: 18093130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.